ClinicalTrials.gg
RecruitingNCT04809350FATUpdated Nov 30, 2023

Human Milk Fortification With Adjustable Versus Targeted Method

An interventional study of Adjustable Human Milk Fortification and Targeted Human Milk Fortification in Growth Failure, sponsored by University of Calgary. Recruiting at 1 site in Canada. Per ClinicalTrials.gov, last updated 2023-11-30.

Sponsored by University of Calgary · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by May 2024, 2 years 5 months ago, but the record still lists the study as recruiting.
  • Started Nov 2023; still recruiting 3 years later.
Phase
Not applicable
Study type
Interventional
Enrollment
52
Allocation
Randomized
Sex
All
01

Study summary

Research question: Do preterm infants born \<1250 g achieve better weight gain with targeted fortification compared with the adjustable fortification of human milk?

Hypothesis: Targeted fortification of human milk results in better weight gain in infants with birth weight \<1250 gr when compared to the adjustable fortification.

Study design: Open-label, pragmatic, parallel randomized controlled trial in appropriate for gestational age infants with birth weight \<1250 g.

Read the detailed description

Human milk is the ideal diet for neonates. However, it does not provide enough energy, protein, and sodium to meet the nutritional requirements of very preterm infants. Postnatal growth failure is common despite the current use of human milk fortifiers. The main human milk fortification methods include:

  1. standard HM fortification (SF) which assumes an average composition of breast milk and adds fortifiers in a fixed dosage. It does not account for variations of nutrient content in human milk
  2. Individualized human milk fortification which encompasses two methods:

    1. Adjustable HM fortification (AF): Protein supplementation is provided in addition to SF according to blood urea nitrogen (BUN) concentration which reflects the infant's metabolic response to protein intake. However, there are clinical scenarios in which the BUN levels are not a reliable marker of protein intake, such as acute kidney injury.
    2. Targeted HM fortification (TF): Based on routine analyses of HM that are used to adjust fortification to meet the recommended requirements for infants. It does not take into consideration that the requirements of infants may vary.

SF has frequently failed to achieve appropriate weight gain, while individualized (AF or TF) fortification seems to have better performance. However, the evidence to support one method over the other is lacking.

The objective of the study is to compare weekly average weight gain between preterm infants on AF versus TF.

Once the written consent is obtained, the infant will be randomized to AF or TF. The sequence code will be kept in sequential numbered sealed envelopes. Infants from multiple births will be included as 1 unit and randomized to the same arm of the study.

For patients allocated to the TF group, breast milk will be analyzed twice weekly for energy, protein, and sodium contents. The daily protein, fat, and sodium intakes will be then calculated and optimized to meet the recommended dietary reference intake (DRI) for preterm infants with birth weight \<1250 g.

For patients allocated to the AF group, weekly BUN measurements will be performed. Based on BUN concentrations, the liquid protein will be added to achieve the targeted BUN level. Additional calories will be added using formula if growth is suboptimal or DRI is not met based on the assumed human milk content for protein and energy.

The intervention will last 4-8 weeks. For all patients, the day the first BUN concentration and milk analyses are done will be day 1 of intervention. The following measurements will be performed on days 7-8, 14-16, 21-23, and 28-30 of intervention: Weight (grams), length and head circumference (centimeters), BUN and sodium concentrations.

Data on maternal and neonatal characteristics will be collected from their electronic and physical charts.

02

Conditions studied

  • Growth Failure

Browse trials for

Keywords

  • Human milk
  • Fortification
  • Preterm infants
03

In context

Failure to Thrive

84 studies on the registry are indexed under Failure to Thrive; 12 are open to participants now.

This study's planned enrollment of 52 is below the median of 100 across 56 interventional studies indexed under Failure to Thrive.

Browse Failure to Thrive studies →

Lead sponsor

University of Calgary is the lead sponsor of 703 studies on the registry; 196 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 2 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Infants with birth weight \<1250 g born at Foothills Medical Centre.
  • Appropriate for gestational age (AGA) (according to Fenton's Charts).

Exclusion criteria

Exclusion Criteria:

  • Abnormal Newborn Metabolic Screen
  • Major congenital anomalies intervention.
  • Patients who develop NEC prior to enrollment.
  • Patients with confirmed congenital Toxoplasmosis, Syphilis, Rubella, Cytomegalovirus, Herpes simplex virus, Varicella and/or Zika (TORCH infections).
  • Patients receiving systemic .
  • Patients with acute kidney injury (AKI).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
52 participants (estimated)

Study arms

  • Active comparator
    Adjustable Human Milk Fortification

    Human milk fortification based on blood urea levels

    Dietary Supplement: Adjustable Human Milk Fortification

  • Experimental
    Targeted Human Milk Fortification

    Human milk fortification based on milk analysis

    Dietary Supplement: Targeted Human Milk Fortification

Interventions

  • Dietary supplementAdjustable Human Milk Fortification

    BUN and sodium concentrations will be measured every week in infants on full enteral feeds with fortified human milk. Liquid protein will be added based on serum urea.

  • Dietary supplementTargeted Human Milk Fortification

    Human milk will be analyzed twice weekly. Before the day of analysis, each mother will store fresh milk pumped from 10:00 AM until 8:00 AM of the previous day in a refrigerator and bring it to the hospital. Protein, fat, and sodium supplementation will be added to the human milk to meet the recommended daily intakes.

06

What researchers measure

Primary outcomes

  1. Average weight gain in infants on Adjustable versus Targeted human milk fortification

    Average weight gain measured as g/kg per day

    Time frame: Weekly for 8 weeks

Secondary outcomes

  1. Anthropometrics in infants on Adjustable versus Targeted human milk fortification

    Measurement of head circumference and length in centimeters.

    Time frame: Weekly for 8 weeks

  2. BUN concentration in infants on Adjustable versus Targeted human milk fortification

    mmol/L

    Time frame: Weekly for 4 weeks

  3. Incidence of extra uterine growth restriction

    Defined as weight less than 10th percentile at 36 weeks corrected age (CA)

    Time frame: At 36 weeks CA

07

Study locations

1 of 1 sites recruiting
  • Foothills Medical Centre
    Calgary, Alberta T2N2T9, Canada
    Recruiting
    • Belal Alshaikh, MD · Contact
    • Belal Alshaikh, MD · Principal investigator
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 30, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04809350
Responsible party
Sponsor
First posted
Mar 22, 2021
Start date
Nov 10, 2023
Primary completion
May 31, 2024 (estimated)
Completion
May 31, 2025 (estimated)
Last update
Nov 30, 2023

Study contacts

Belal N Alshaikh, MD, MSc
Contact
balshaik@ucalgary.ca
4039561588
Adriana Reyes Loredo, MD
Contact
adriana.reyesloredo@albertahealthservices.ca
Belal Alshaikh, MD, MSc
principal investigator · University of Calgary

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion